KẾT QUẢ ĐIỀU TRỊ CỦA DOCETAXEL TRÊN BỆNH NHÂN UNG THƯ TUYẾN TIỀN LIỆT DI CĂN KHÁNG CẮT TINH HOÀN SAU THẤT BẠI ĐIỀU TRỊ BƯỚC MỘT VỚI ABIRATERONE ACETATE

Abstract

Objective: Evaluation of outcomes with Docetaxel in patients with metastatic castration-resistant prostate cancer after first-line failure of Abiraterone acetate. Patients and methods: A cross-sectional descriptive study on 40 patients with metastatic castration-resistant prostate cancer after first-line failure of Abiraterone acetate in Vietnam National Cancer Hospital from January 2014 through May 2023. Kaplan-Meier curves were used to estimate the time to treatment failure Results: The mean age of the patients was 71,5 (± 7,6), median PSA pretreatment was 88,9 ng/ml (IQR: 14,4-137,8). The median number of Docetaxel cycles was 5 cycles (1-10). The rate of patients achieving PSA decline ≥ 30% was 50% and PSA response was 27,5%. The median time to treatment failure with Docetaxel was 4,9 months (95% CI: 1,2-8,6). Time to treatment failure with Abiraterone <12 months, Docetaxel cycles < 6, and PSA decline < 30% are factors that have a significantly lower time to treatment failure with Docetaxel (p < 0,001). Conclusion: The rate of patients who achieved PSA response was 27,5%, and the median time to treatment failure with Docetaxel was 4,9 months (95% CI: 1,2-8,6).